FDA Approves Arymo ER (morphine sulfate), New Abuse-Deterren
The US Food and Drug Administration (FDA) announced the approval of Arymo ER (morphine sulfate) tablets C-II for the management of pain “severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate,” noted a press release from the manufacturer Egalet Pharma.

Arymo ER is manufactured with Egalet’s proprietary Guardian Technology—a physical and chemical barrier approach to abuse deterrence without the use of an opioid antagonist. The technology uses a polymer matrix that “results in tablets that are hard and difficult to manipulate for misuse and abuse. This approach offers the ability to design tablets with controlled-release profiles as well as physical and chemical properties that have been demonstrated to resist both common and rigorous methods of manipulation,” noted the company....

https://www.practicalpainmanagement.com/resources/news-and-research/fda-approves-arymo-er-morphine-sulfate-new-abuse-deterrent-opioid
Like
Comment
Share